Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30332358 | 0.94 | HSD11B1 (0.47) | MAPK8SMYD3HPGDNPC1RAB9A | |
| SCHEMBL4705235 | 0.93 | GRM5 (0.48) | HPGDNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL4283681 | 0.93 | HPGD (0.49) | HPGDNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL1876540 | 0.92 | HPGD (0.51) | HPGDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4440234 | 0.92 | HPGD (0.51) | HPGDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL3937594 | 0.90 | SMYD3 (0.52) | SMYD3 | |
| SCHEMBL15416709 | 0.89 | CNR2 (0.46) | SMYD3NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL30675640 | 0.89 | SMYD3 (0.53) | SMYD3 | |
| Hydrochloric Acid SCHEMBL30675644 | 0.89 | SMYD3 (0.53) | SMYD3 | |
| SCHEMBL8226069 | 0.86 | SIGMAR1 (0.44) | SMYD3ALDH1A1L3MBTL1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007009690-A1 | HETEROCYCLYL-SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A (ES) | 2007-01-25 | — | — | WO | claimed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | MAPK8 357/4885SMYD3 3261/4885HPGD 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.